MAG / Siglec-4a

MAG / Siglec-4a Overview

English NameMyelin-associated glycoproteinApproved Drugs0
Drugs in Clinical Trials1Target SynonymMAG,Siglec-4a,GMA,Sialic Acid Binding Ig-Like Lectin 4A,Myelin-Associated Glycoprotein,SIGLEC4A,S-MAG,SPG75,Myelin Associated Glycoprotein,Sialic Acid-Binding Immunoglobulin-Like Lectin 4A
Highest Development StagePhase 2 Clinical
English NameMyelin-associated glycoprotein
Target SynonymMAG,Siglec-4a,GMA,Sialic Acid Binding Ig-Like Lectin 4A,Myelin-Associated Glycoprotein,SIGLEC4A,S-MAG,SPG75,Myelin Associated Glycoprotein,Sialic Acid-Binding Immunoglobulin-Like Lectin 4A
Approved Drugs0
Drugs in Clinical Trials1
Highest Development StagePhase 2 Clinical

MAG / Siglec-4a Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Human (3)Mouse (1)

  • Tag

    His Tag (1)Fc Tag (1)His Tag & Avi Tag (2)

  • Conjugate

    Unconjugated (2)Biotin-labeled (2)

MAG / Siglec-4a Background

Myelin-associated glycoprotein (MAG), a nervous system cell adhesion molecule, is an I-type lectin that binds to sialylated glycoconjugates, including gangliosides bearing characteristic structural determinants. Preferentially binds to alpha-2,3-linked sialic acid. Binds ganglioside Gt1b. Adhesion molecule that mediates interactions between myelinating cells and neurons by binding to neuronal sialic acid-containing gangliosides and to the glycoproteins RTN4R and RTN4RL2. Protection against apoptosis is probably mediated via interaction with neuronal RTN4R and RTN4RL2. In dorsal root ganglion neurons the inhibition is mediated primarily via binding to neuronal RTN4R or RTN4RL2 and to a lesser degree via binding to neuronal gangliosides. In cerebellar granule cells the inhibition is mediated primarily via binding to neuronal gangliosides. In sensory neurons, inhibition of neurite extension depends only partially on RTN4R, RTN4RL2 and gangliosides.

MAG / Siglec-4a Synonyms

MAG,Siglec-4a,GMA,S-MAG

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AXER-204AXER-204Phase 2 ClinicalRenetx Bio IncCardiovascular Diseases
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland